Related Experiment Video
Updated: Dec 15, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.6K
[Androgen deprivation therapy in advanced prostate cancer. Multicenter study.]
Victor José Valencia-Guadalajara1, Laura Martínez-Cayuelas2, Pau Sarrió-Sanz1
1Hospital Universitari Sant Joan d'Alacant. Alicante. España.
Archivos Espanoles De Urologia
|July 8, 2020
Summary
Advanced prostate cancer (PC) patients on androgen deprivation therapy (ADT) show varied responses. High PSA at diagnosis, unfavorable histology, and failure to achieve undetectable PSA predict progression to castration-resistant prostate cancer (CRPC).
Area of Science:
- Oncology
- Urology
Background:
- Advanced prostate cancer (PC) is a significant clinical challenge.
- Androgen deprivation therapy (ADT) is a standard treatment for advanced PC.
- Understanding factors predicting treatment resistance is crucial for patient management.
Purpose of the Study:
- To describe a cohort of advanced PC patients undergoing ADT in routine clinical practice.
- To identify clinical parameters associated with the development of castration-resistant prostate cancer (CRPC).
Main Methods:
- A multicenter, observational, retrospective study.
- Analysis of 952 patients treated with ADT between January 2016 and January 2017.
- Descriptive statistics and Kaplan-Meier analysis for progression times.
Main Results:
- 29.6% of patients progressed to CRPC.
- Predictors of CRPC included PSA >30 ng/ml at diagnosis (OR 2.78), Gleason score group 4-5 (OR 2.33), and failure to achieve undetectable PSA after ADT (OR 3.32).
- Patients with unfavorable histology and those not achieving undetectable PSA progressed more rapidly.
Conclusions:
- Patient responses to ADT in advanced PC are heterogeneous.
- Elevated PSA at diagnosis, unfavorable histology, and failure to reach PSA <0.1 ng/ml after ADT are indicators of progression to CRPC.
